Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „dose“
Suchtreffer
Begriffe & Kennungen
Alecensa · 4.5 · CYP3A inducers Co-administration of multiple oral doses of 600 mg rifampicin once daily, a strong CYP3A induce
Eintrag öffnenAlecensa · 4.5 · CYP3A inhibitors Co-administration of multiple oral doses of 400 mg posaconazole twice daily, a strong CYP3A i
Eintrag öffnenAlecensa · 4.5 · Medicinal products that increase gastric pH Multiple doses of esomeprazole, a proton pump inhibitor, 40 mg onc
Eintrag öffnenAlecensa · 4.5 · Multiple doses of 600 mg alectinib had no influence on the exposure of midazolam (2 mg), a sensitive CYP3A sub
Eintrag öffnenAlecensa · 4.8 · 10 2.3 % and 3.6 % of the patients, respectively) or dose reduction (1.7 % and 1.5 %, respectively). In 1.3 %
Eintrag öffnenAlimta · 4.5 · In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-in
Eintrag öffnenAlli (previously Orlistat GSK) · 4.5 · A decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number
Eintrag öffnenAloxi · 4.5 · In a clinical study, no significant pharmacokinetic interaction was shown between a single intravenous dose of
Eintrag öffnenAloxi · 4.8 · In clinical studies at a dose of 500 micrograms (total 161 patients) the most frequently observed adverse reac
Eintrag öffnenAloxi · 4.8 · In clinical studies in adults at a dose of 250 micrograms (total 633 patients) the most frequently observed ad
Eintrag öffnenAlpha-Mannosidose
Eintrag öffnenAlpha-Mannosidose, adulte Form
Eintrag öffnenAlpha-Mannosidose, infantile Form
Eintrag öffnenAlunbrig · 4.5 · 9 discontinuation of a strong CYP3A inhibitor, Alunbrig should be resumed at the dose that was tolerated prior
Eintrag öffnenAlunbrig · 4.5 · In healthy subjects, coadministration of multiple 600 mg daily doses of rifampicin, a strong CYP3A inducer, wi
Eintrag öffnenAlunbrig · 4.8 · Dose reduction for CPK elevation occurred in 10% of patients at the 180 mg regimen (see sections 4.2 and 4.4).
Eintrag öffnenAlunbrig · 4.8 · Dose reduction for elevation of ALT and AST occurred in 0.7% and 1.1% of patients, respectively at the 180 mg
Eintrag öffnenAlunbrig · 4.8 · Dose reduction for elevation of lipase and amylase occurred in 4.7% and 2.9% of patients, respectively at the
Eintrag öffnenAlunbrig · 4.8 · Dose reduction for visual disturbance occurred in two patients (0.7%) at the 180 mg regimen (see sections 4.2
Eintrag öffnenAlunbrig · 4.8 · No patients had dose reductions due to hyperglycaemia.
Eintrag öffnen